Shattuck Labs (NASDAQ:STTK) Downgraded to “Neutral” at BTIG Research

BTIG Research downgraded shares of Shattuck Labs (NASDAQ:STTKFree Report) from a buy rating to a neutral rating in a research note issued to investors on Monday, MarketBeat reports.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $28.00 target price on shares of Shattuck Labs in a research report on Wednesday, May 15th. Needham & Company LLC dropped their price objective on shares of Shattuck Labs from $12.00 to $8.00 and set a buy rating on the stock in a report on Friday, June 14th.

View Our Latest Stock Analysis on STTK

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $4.17 on Monday. The stock’s 50-day moving average is $8.49 and its 200-day moving average is $8.32. The company has a market cap of $198.05 million, a P/E ratio of -2.16 and a beta of 1.85. Shattuck Labs has a 52-week low of $1.33 and a 52-week high of $11.76.

Shattuck Labs (NASDAQ:STTKGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The firm had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. The business’s revenue for the quarter was up 2200.0% compared to the same quarter last year. As a group, equities analysts predict that Shattuck Labs will post -1.56 EPS for the current year.

Institutional Trading of Shattuck Labs

Hedge funds have recently modified their holdings of the company. Cannon Global Investment Management LLC acquired a new stake in shares of Shattuck Labs in the first quarter valued at $91,000. Virtu Financial LLC acquired a new stake in Shattuck Labs in the 1st quarter valued at about $113,000. Tower Research Capital LLC TRC raised its stake in shares of Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after acquiring an additional 5,989 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Shattuck Labs during the first quarter worth approximately $174,000. Finally, Reliant Investment Management LLC bought a new stake in shares of Shattuck Labs during the fourth quarter valued at approximately $143,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Featured Stories

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with's FREE daily email newsletter.